Novartis crizanlizumab shows promise in sickle cell anaemia
A new analysis has shown that Novartis’ crizanlizumab reduced the number of patients with sickle cell disease experiencing a pain crisis.
9th October 2018
Latest news
Affimed shares plunge on trial death
Shares in German biopharma Affimed dropped near 30% after the company said it was placing a key Phase I programme of its experimental cancer immunotherapy on hold because of serious side effects observed in trials, including a patient death.
9th October 2018
Diurnal shares plummet on trial failure
Shares in UK speciality pharma Diurnal plummeted more than 50 percent on news that a late-stage study of an experimental treatment for congenital adrenal hyperplasia (CAH) failed to meet its primary objective.
9th October 2018
The PharmaTimes Medical & Scientific Excellence Awards – could it be you?
Do you have a passion for medical information? Could you be among the first in the field to win at the hotly anticipated PharmaTimes Medical & Scientific Excellence Awards?
9th October 2018
Novartis files MS drug siponimod in EU and US
Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.
9th October 2018
New UK biopharma Sitryx launches with $30m fundraising
New UK biopharmaceutical group Sitryx has launched operations with $30 million to help it develop disease-modifying therapeutics in immunometabolism.
9th October 2018
Mixed data for Xencor’s SLE drug
Xencor’s experimental systemic lupus erythematosus (SLE) drug XmAb5871 has failed to hit its key target in a mid-stage study.
9th October 2018
Four new therapies to be funded by NHS Scotland
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
9th October 2018
Stelara induces remission in ulcerative colitis patients
Janssen has presented new data showing that a single dose of its biologic Stelara induced clinical remission and response in patients with moderate to severe ulcerative colitis.
9th October 2018
NICE expands backing for Pfizer’s Mylotarg
NICE is recommending Mylotarg for previously untreated, de novo, CD33-positive acute myeloid leukaemia in combination with chemotherapy.
8th October 2018
US nod for Akcea/Ionis’ Tegsedi
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
8th October 2018
EU regulators to review bluebird’s gene therapy LentiGlobin
The European Medicines Agency will undertake an accelerated review of bluebird bio’s LentiGlobin, a gene therapy for the treatment of transfusion-dependent beta-thalassemia.
8th October 2018
Gilead strikes deal with NHS England on Yescarta access
Gilead has struck a deal with NHS England that allows some adults with lymphoma access to its “game-changing” CAR-T therapy Yescarta.
8th October 2018
Demonstrate your skills and expertise
The highly anticipated Medical & Scientific Excellence Awards close for entry in just a few weeks (31 October). This is your chance to stand out against the competition, enter now to get the recognition you deserve.
5th October 2018
MHRA consults on new regulatory framework for ‘no-deal’ scenario
The Medicines and Healthcare products Regulatory Agency has launched a consultation seeking views on how its legislation and regulatory processes would have to be modified if the UK leaves the EU under a ‘no-deal’ scenario.
5th October 2018
